Article

Living Donors: Vaccination Prevents Hep B Infection

Author(s):

Active immunization for hepatitis B can be a cheaper, safe way to prevent infections that occur when liver transplant recipients are infected by donors' organs.

Transplant recipients getting a partial liver from a living donor can contract hepatitis B.

These infections can be prevented with post-transplant prophylaxis.

But the issues of developing resistance to these expensive antiviral drugs make their use impractical, a research team reports.

In an abstract presented April 24 at the 2015 International Liver Congress in Vienna, Austria, Poh Yen Loh of the Changi General Hospital in Singapore and colleagues in Kaohsiung, Taiwan looked at a new routine for treating a group of 71 transplant patients.

All were recipients of livers and all got HBV vaccinations before their transplants.

They were divided into 3 groups based on their response to the vaccination.

Group on had an anti-HB titer of at least 1000 IU/L at the time of transplant. Group 2 showed no response to pre transplant vaccination but developed an anti-HB titer of at least 100 IU/L after transplantation.

Group 3 had no response to either vaccination. They were given lamivudine afterwards, for an indefinite period.

The only group that developed a hepatitis B infection after transplant was group 3.

“Active immunization is effective in preventing de novo hepatitis B in adult living donor liver transplantation,” by keeping pre transplant anti-HB levels of more than 1000 IU/L and post-transplant anti-HBs of greater than 100 IU/L, they wrote. “With vaccination lamivudine can be stopped in patients who achieve post-transplant of anti-HBs lvel of more than 100 IU/L.”

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.